Aims: Adiposity is associated with an increased but also with a decreased risk for successive vascular events or mortality in patients with different manifestations of vascular disease. In this study we directly compare the risk of general adiposity or abdominal obesity on the occurrence of new vascular events or mortality in these patients. Methods: Patients with cerebrovascular disease (CVD; n ¼ 973), coronary artery disease (CAD; n ¼ 2339) or peripheral arterial disease (PAD; n ¼ 894) were prospectively followed for the occurrence of a vascular event or death. The median follow-up was 4.5 years. Adiposity was assessed with body mass index (BMI), waist circumference (WC) and determination of intra-abdominal fat through ultrasound. Cox proportional hazards models were used to evaluate the risk for new vascular events, vascular mortality and all-cause mortality. Results: CAD patients had a 12% increased risk for vascular mortality with 1 BMI unit increase (hazard ratio (HR) 1.12; 95% confidence interval (CI) 1.05-1.20) and a 25% increased risk with 1cm increase in intra-abdominal adipose tissue (HR 1.25; 95% CI 1.12-1.39). The risk for all-cause mortality was increased by 3% (HR 1.03; 95% CI 1.01-1.05) with 1 cm increase in WC and was increased by 15% (HR 1.15; 95% CI 1.06-1.25) with 1 cm increase in intra-abdominal adipose tissue. In PAD patients there was an inverse relationship between BMI and vascular mortality (HR 0.93;) and all-cause mortality (HR 0.90; 95% CI 0.86-0.94). In CVD patients there was no relation between obesity and vascular events or mortality. Conclusion: General adiposity is associated with an increased risk for vascular mortality in CAD patients and a decreased risk for (vascular) mortality in PAD patients.
Introduction
Adiposity, especially abdominal obesity, is a well-known risk factor for the occurrence of cardiovascular disease and mortality in the general population. [1] [2] [3] Abdominal obesity is related to metabolic changes, such as dyslipidaemia, type 2 diabetes mellitus, hypertension, inflammation and hypercoagulability, which are all associated with an increased cardiovascular risk. 4, 5 Many studies focused on the relation between obesity and first-ever cardiovascular events in patients without a history of vascular disease, 1, [6] [7] [8] [9] [10] [11] [12] including a recent publication, 12 which incorporated 58 prospective studies. Meta-analysis of these studies showed strong associations between adiposity measurements and first-ever cardiovascular disease.
As trends in cardiovascular death rates are decreasing in most Western societies, the number of patients surviving a vascular event is simultaneously increasing. 6 This emphasizes the importance of secondary prevention in patients with a (recent) history of vascular disease, knowing that these patients are at an elevated risk for future cardiovascular events as well as mortality. 13 Subsequent clinical vascular events mainly occur within the same location of the vascular tree as the first event, 14 but patients are also at a risk of developing vascular diseases at other locations. 15 The risk for subsequent vascular events or mortality depends on the location of the prior vascular event, 16 but the risk of adiposity with its various manifestations has not yet been assessed. In patients with cerebrovascular disease (CVD), obesity is associated with an increased risk for vascular mortality and all-cause mortality, 13 and presumably also for recurrent stroke. 17 Patients with peripheral arterial disease (PAD) are at an increased risk for myocardial infarction (MI), stroke and vascular mortality, an association found without considering the role of obesity within this process. 18, 19 In patients with coronary artery disease (CAD), the reported relationship between obesity and vascular outcomes and mortality is unclear; both positive and negative associations have been reported. 20 An inverse relation between obesity and outcome is also referred to as 'obesity paradox'. A direct comparison of the relation between general adiposity, as measured by body mass index (BMI), and vascular risk between groups of patients with various clinical manifestations of vascular diseases showed an inverse relationship between BMI and vascular mortality in patients with CAD or PAD, but not in patients with previous stroke or transient ischaemic attack. 21 The primary objective of the present prospective cohort study was to directly compare the risk of general adiposity and abdominal obesity on the occurrence of vascular events and mortality in patients with various clinical manifestations of vascular disease.
Materials and methods

Study population
The study cohort consists of patients from the Secondary Manifestations of ARTerial disease (SMART) study, an ongoing prospective single-center cohort study at the University Medical Center Utrecht that started in September 1996. The study was approved by the Ethics Committee of the University Medical Center Utrecht and all patients gave their written informed consent. Study rationale and detailed description are published elsewhere. 22 Measurements of (abdominal) adiposity BMI, the weight in kilograms divided by the square of the height in metres, was computed after a standardized anthropometric measurement protocol. Waist circumference (WC) was measured as the circumference in centimetres halfway between the lower rib and the iliac crest. In addition, patients underwent ultrasonographic intra-abdominal fat measurement, a validated method to quantify abdominal adipose tissue, 4 which was performed at three different sites and was determined as the mean distance between the peritoneum and the lumbar spine.
Follow-up
During follow-up, patients were asked to fill out a questionnaire biannually, to report newly diagnosed diseases and hospital admissions. When suspected for a cardiovascular event, patients' medical records and documentation were retrieved from their treating specialist or general practitioner. For those who died, specific cause of death was retrieved (also through general practitioner or specialist) to differentiate between vascular and non-vascular causes of death. Suspected vascular events and mortality were assessed separately by three non-treating specialists. Study endpoints included ischaemic stroke, MI, vascular mortality and all-cause mortality. Complete definitions of these study endpoints are defined in Table 1 . The definite endpoint was scored upon majority of evaluation. Patients were followed up until March 2009.
Data analyses
Central estimators and variance measures were calculated for baseline characteristics for each of the three adiposity measurements. Cox proportional hazards models were applied to vascular disease-specific strata after confirming that the assumptions of proportionality were met. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the occurrence of first new vascular events as well as mortality were computed. Besides univariate analyses with the three specific adiposity measurements as predictors for each study outcome, two other models were applied to account for the potential confounding factors age (years), gender, smoking (packyears), systolic blood pressure, prevalent diabetes and dummy variables for history of vascular disease before inclusion into the cohort. In order to directly compare the different measurements on their risk of vascular events and
General and abdominal adiposity and risk of vascular events DA Kanhai et al mortality, stratum-specific s.d.'s of the adiposity measurements were calculated. Analyses with WC and intra-abdominal adipose tissue ultrasound were carried out in patients included in the cohort after January 2000, as these measurements were then performed in all patients. Missing values for WC and intraabdominal fat measurement were observed in 4.1 and 5.7% of the patients, respectively. Single imputation techniques were applied to make amends for these missing data. There were no missing data for BMI.
Data analyses were conducted using SPSS version 18 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
A total of 4206 patients were included in this study: CVD (n ¼ 973), CAD (n ¼ 2339) and PAD (n ¼ 894). Baseline General and abdominal adiposity and risk of vascular events DA Kanhai et al characteristics of the patients are shown in Table 2 . The obesity parameters BMI, WC and adipose tissue ultrasound were in general slightly higher in CAD patients.
Relation between BMI and vascular events or mortality During a median overall follow-up of 4.5 years with a total of 21 047 patient years, 677 different endpoints were observed, incorporating ischaemic stroke (n ¼ 138), MI (n ¼ 293), vascular mortality (n ¼ 270), composite vascular endpoint (n ¼ 491) and all-cause mortality (n ¼ 473). In patients with CAD, an increase in 1 unit of BMI was associated with a 12% higher risk for vascular mortality (HR 1.12; 95% CI 1.05-1.20; Table 3 ). In patients with PAD, the risk for vascular mortality and all-cause mortality was lower at higher BMIs (HR 0.93; 95% CI 0.87-0.98; and HR 0.90; 95%CI 0.86-0.94, respectively). In patients with CVD, no statistically significant associations were observed between BMI and vascular events or mortality.
Relation between WC or intra-abdominal adipose tissue and vascular events or mortality There was no relation between WC and future ischaemic stroke, MI or the composite vascular endpoint in any of the three patient groups (Table 4 ). In patients with CAD, the risk for vascular mortality was 5% higher for each 1-cm increase in WC (HR 1.05; 95% CI 1.02-1.08) and 3% higher for all-cause mortality (HR 1.03; 95% CI 1.01-1.05). There was no relation between WC and vascular endpoints or mortality in CVD patients or patients with PAD. In patients with CAD, an increase in 1 cm of ultrasound intra-abdominal adipose tissue was associated with an increased risk for the composite vascular endpoint (HR 1.09; 95% CI 1.01-1.18), for vascular mortality (HR 1.25; 95% CI 1.12-1.39) and for all-cause mortality (HR 1.15; 95% CI 1.06-1.25; Table 5 ). In patients with CVD or PAD, there was no relation between intra-abdominal adipose tissue and vascular events or mortality.
Comparison of the risk of adiposity measurements on vascular events and mortality In patients with CAD, the effect of 1 s.d. increase in abdominal adiposity measurements was associated with the highest increase in risk for vascular events and mortality compared with 1 s.d. increase in BMI (Table 6 ).
Discussion
In a cohort of patients with different clinical manifestations of arterial vascular disease, general adiposity, but even more abdominal obesity, is associated with an increased risk for vascular and all-cause mortality in patients with CAD. In PAD patients there was an inverse relation between General and abdominal adiposity and risk of vascular events DA Kanhai et al General and abdominal adiposity and risk of vascular events DA Kanhai et al general adiposity and risk for vascular and all-cause mortality. There was no relation between general adiposity or abdominal obesity and subsequent ischaemic stroke or MI in CAD, PAD or CVD patients.
In a systematic review of 40 cohort studies, 20 overweight and mildly obese CAD patients had a lower risk for future vascular events and all-cause mortality. The authors explained their finding by the lack of discriminatory power of BMI to differentiate between body fat and lean body mass, a distinction we were able to make in this study by adding two abdominal adipose tissue parameters. Being able to assess the role of abdominal obesity, we think that major additional risk factors for mortality are produced by abdominal adipose tissue. Adipocytes exert important endocrine functions by secreting adipocytokines, and abdominal adipose tissue may have a different secretory profile compared with subcutaneous adipose tissue. These adipocytokines were shown to have an impact on survival after manifest cardiovascular disease. 23 Therefore, in agreement with the findings of the systematic review, there seems to be indeed a lack of discriminatory power of BMI, rendering it insufficient to explore the relationship between obesity and mortality in these patients.
In this study, PAD patients had 7% lower risk for vascular mortality and 10% lower risk for all-cause mortality for each 1 unit increase in BMI. This inverse relationship was not observed with an increase in abdominal obesity measurements such as WC and abdominal ultrasound. The finding of this 'obesity paradox', a phenomenon where elevated BMI is associated with improved survival, could be explained by the presence of vascular disease itself. Patients with PAD have severe atherosclerosis and higher muscle atrophy, expressed as lower lean muscle mass, presumably due to reduced mobility. An increase in BMI or lean muscle mass, interpreted in an increase in mobility, accompanies better survival. Patients with PAD do not have lower abdominal adipose tissue parameters compared with patients with other manifestations of vascular disease (Table 2) , which could be an explanation for the lack of an association between abdominal obesity and mortality-related endpoints in these patients.
The various studies that assessed the association between obesity and vascular events and mortality in PAD patients report different types of relationship, varying from positive relations 10, 24 to an obesity paradox. 25 Although obesity altered the risk for vascular mortality and all-cause mortality in CAD and PAD patients, no relationship between obesity and mortality was observed in CVD patients. The fact that there was no relationship between obesity and ischaemic stroke in these patients is an interesting finding, as recurrent stroke prevention guidelines state that weight reduction may be considered for all overweight ischaemic stroke and TIA patients to maintain the goal of a BMI between 18.5 and 24.9 kg m À2 . 17 The authors of these guidelines do acknowledge that this recommendation is not evidence based, but is established by the presumption that obesity is a contributing factor to other vascular risk factors.
New vascular events in patients with a (recent) clinical manifestation of vascular disease often occur within the same area of the vascular tree. In this study we observed that this was also the case with the endpoints ischaemic stroke and MI in the strata of vascular disease (CVD and CAD, respectively); yet this phenomenon of disease recurrence was not obesity dependent.
There was a relation of general and abdominal obesity with mortality endpoints, but not with non-fatal vascular events. A possible explanation for this difference could be inflammation. Obesity leads to chronic inflammation, which may stimulate the migration and activation of macrophages in the cap of atherosclerotic plaques. This may contribute to a higher risk of plaque rupture, leading to acute arterial thrombosis and subsequent fatal events. 26 Another explanation for the relation between obesity and mortality may be the role of obesity in higher incidence of cancer 27 as well as cancer-related mortality. 28 In this study cancer was a frequent cause of nonvascular mortality; in 73% of the non-vascular mortality cases, cause of death was malignancy related. The strength of this study is the precise measurement of abdominal obesity and the large prospective cohort with a large number of hard clinical endpoints. The study limitations should also be considered. Weight and abdominal obesity were measured at baseline and could have changed during follow-up. We also postulate the effect of adipokines on cardiovascular events, but unfortunately no data concerning these markers are available in this cohort.
In conclusion, in patients with CAD, general obesity, but moreover abdominal obesity, is associated with an elevated risk of vascular mortality, whereas abdominal obesity confers an increased risk for all-cause mortality. In PAD patients an inverse relationship was seen between general obesity and vascular mortality and all-cause mortality. In CVD patients there was no relation between (abdominal) obesity and cardiovascular outcome. These findings are in line with the observation that obesity has an important role in the occurrence of first-ever cardiovascular events. 12 
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